• Net Element’s reverse merger with EV manufacturer Mullen Technologies expected to close by 4Q2020
• NETE expects to begin marketing Dragonfly K50, sold in conjunction with JV partner Qiantu Motors from 2Q2021
• Company will also break ground in early 2021 on 1.5 million square foot facility to manufacture, assemble its own vehicles
• Zacks forecasts that NETE could snag $30/share valuation by merger’s close

Net Element Inc. (NASDAQ: NETE), a financial technology company which has recently transformed its business model to become a pure-play electric vehicle (“EV”) manufacturer, was recently the subject of a company initiation report published by Zacks Small-Cap Research (https://ibn.fm/XGMRy). Following from Net Element’s decision to enter into a binding Letter of Intent to merge with privately-held Mullen Technologies Inc. in mid-June 2020, the company has sought to divest itself of its legacy payments-as-a-service transactional model and alter its operational focus towards the electric vehicle space. Now, having utilized Net Element’s EV manufacturing peer group’s average valuation of 10x EV/Sales as a comparable, Zacks Small-Cap Research has forecast that Net Element’s share price could be worth $30.00 once the Mullen reverse-merger is fully complete.

The completion of the triangular reverse merger between Net Element and Mullen Technologies is conditional on the combined entity receiving NASDAQ approval along with the completion of a $10 million capital raise, with Zacks anticipating the deal to close by 4Q2020.

During a recent presentation carried out by Mullen Technologies at JP Morgan’s Virtual Auto Conference, the company announced that it would partner with Chinese EV manufacturer, Qiantu Motors to market and sell its vehicles in the United States – with Mullen Technologies having reportedly arrived at an agreement to sell Qiantu’s Dragonfly K50 from 2Q2021 onwards.

Separately, the company also revealed that it had entered into a letter of intent with the City of Spokane to build a 1.5 million sq. ft. facility to manufacture and assemble vehicles, with work on the facility set to commence in early 2021. Remarkably, Mullen Technologies has also revealed that it expects to get to its production phase with as little as $400 million in invested capital over five years (compared to the $1 billion traditionally required) due to its current vehicle IP, which has already been two years in the making.

In addition to its partnership with Qiantu Motors, Mullen Technologies now plans to introduce its self-manufactured EV SUV, the Mullen MX-5 by the second quarter of 2022, with hopes to reach a production threshold of 35,000 vehicles per annum by 2026.

With Net Element’s existing shareholders expected to own between 15% and 21.7% of the post-merger amalgamated entity and utilizing a 10x enterprise value to sales multiple, Zacks Investment Research have estimated that NETE shares could be worth $70 per share by 2023, assuming no further equity dilution. However, by taking a conservative approach which has factored in risk and dilution and time, Zacks’ equity research team believes that the share price could easily surpass the $30 per share mark once the deal closes.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• In its most recent SEC filings, WTER announced record first-quarter revenue of $14.2 million
• Alkaline88 ranked as 10th best-selling value-added water and third fastest-growing value-added water in Nielsen report
• WTER marks milestone by adding the largest food-service redistributor to its growing list of channel partners

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) continues its impressive upward trajectory, releasing record numbers in its latest financial report and ranking in a top-10 category in a recent Nielson report. In addition, with the announcement of its recent distribution agreement with DOT Foods, the company is aggressively expanding into the hospitality channel.

In its most recent SEC filings, WTER announced that it delivered a record first-quarter revenue of $14.2 million (http://ibn.fm/itVOo), representing a revenue increase of approximately 40% year over year and 18% sequentially. The company also reported fiscal first-quarter earnings per share of ($0.05), which improved 57% compared to the prior-year quarter. In addition, during its most recent earnings call, The Alkaline Water Company indicated that its July’s purchase orders were the second highest of any month.

“Fiscal 2021 is off to a solid start with strong momentum across all our lifestyle brands,” said WTER president and CEO Richard A. Wright. “We delivered record fiscal Q1 revenue of $14.2 million and showed operational discipline with expenses down 5% year-over-year. During the last six months, we have performed exceptionally well, and according to Nielsen data, we outperformed the value-add water category by approximately 12% on a dollar sales basis and 16% on a unit basis. Our operational excellence during the pandemic is creating significant goodwill with existing channel partners, who are showing a stronger commitment to our brands, especially our single-serve, aluminum, and flavored water offerings.”

In addition, the recent “pantry-stuffing” run on basic essential resulted in a significant boon for The Alkaline Water Company. “During the pandemic, Alkaline88(R) was able to meet our retailer’s demands,” said Wright (http://ibn.fm/dLMvc). “We believe that up to 30% more households tried our water during our fiscal Q4. This is highlighted by the recent Nielsen report, where Alkaline88(R) was ranked as the 10th best-selling value-added water, and the third fastest-growing, top-ten, value-added water in the country during the 13 weeks ending May 16, 2020.”

Finally, The Alkaline Water Company recently announced a partnership with DOT Food Inc., which will offer the entire line of Alkaline88, A88 Flavor Infused waters, and eco-friendly aluminum bottles to its 4,300 customers nationwide by September 21, 2020 (http://ibn.fm/8WBHG). “Adding the largest food-service redistributor, Dot Foods, to our growing list of channel partners is another milestone for the company,” said Wright.

“Every year, Dot Foods sells millions of cases of beverages to its customers,” he continued. “This relationship will give us an entry into the hospitality industry, which we view as a significant opportunity for our growing lifestyle brands. There are over 600,000 restaurants and food-service establishments that will now have access to our full line of products. The U.S food-service industry is nearly equal in size to food retailing and accounted for over $969.4 billion in sales in 2019. Our lifestyle brand extension into flavors and aluminum bottles is one of the major reasons Dot Foods viewed Alkaline88 as an important brand to add to its portfolio of products.”

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies.

To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• Poland trials will include the first ever Phase 1 trial for pediatric patients suffering from glioblastoma multiforme
• CNS Pharmaceuticals has made significant strides in its Berubicin manufacturing process due to its dual-track approach and expects to begin production of its drug candidate at Pharmaceuticals International during the third quarter of 2020
• The Company’s CFO recently acquired 142,000 shares of common stock in the open market, a move indicative of his confidence in the success of Berubicin clinical trials and its positive impact on the global brain tumor therapeutics market

CNS Pharmaceuticals (NASDAQ: CNSP) is moving forward with clinical trials of its innovative leading drug candidate Berubicin in Poland after sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1) has identified a contract research organization to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph).

WPD Pharmaceuticals, which has a sublicense agreement with CNS which gives it commercial rights to Berubicin in selected territories in Europe and Asia, announced that it engaged the services of Worldwide Clinical Trials to supervise Phase 1 and Phase 2 trials. Worldwide Clinical Trials is a full-service drug development company serving the pharmaceutical and biotechnology sectors, from early phase and bioanalytical sciences to Phase 2 and 3 trials and peri-approval studies.

Berubicin is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. In Poland, WPD will conduct the first-ever Phase 1 trial in pediatric GMB patients and an adult Phase 2 trial. Sixty percent of the program will be funded by WPD via a $6 million reimbursement grant from the EU/Polish National Center for Research and Development.

News of the Poland clinical trials comes after CNS Pharmaceuticals announced the achievement of key milestones in its Berubicin manufacturing process and after the acquisition of common stock an officer of the company. The company’s Chief Financial Officer, Christopher Downs, filed an SEC Form 4 on August 25, 2020. SEC Form 4 shows that he acquired 142,000 in common stock through multiple trades at prices ranging from $1.84 to $2.30 (http://ibn.fm/BGb6w).

The common stock acquisition is a bold expression of the confidence Downs has in Berubicin trials and the impact of its lead drug candidate on a growing brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (http://ibn.fm/2Lfjl). Due to the lack of specific therapies that deliver the drugs through the blood-brain barrier, the survival rate for most patients past three years is only 2-5%. Berubicin could potentially change the survival rates with the infiltration of the blood-brain barrier.

The filing occurred on the same day the company provided an update on their Food and Drug Administration filing for the Investigational New Drug (“IND”) application. CNS plans to file the IND application during the fourth quarter of 2020. At the time, the company also announced the completed synthesis of Berubicin active pharmaceutical ingredient (“API”). It was shipped to both manufacturers CNS is working with — U.S.-based Pharmaceutics International Inc. (“Pii”) and Italy-based BSP Pharmaceuticals S.p.A. (“BSP”) — for the preparation of an injectable form of the drug for clinical use.

On September 3, 2020, the company announced significant advancements in its Berubicin manufacturing process due to its dual-track manufacturing strategy, which helped mitigate any possible delays caused by COVID-19, as well as diversify the supply and localized availability of the drug (http://ibn.fm/r7scX). With the API in hand, Pii and CNS have an agreed-upon manufacturing procedure and packaging components. The selection of a sterile filter manufacturer has also been made. The lyophilization cycle has been successfully simulated by CNS and Pii, including a completed draft of the batch record.

CNS believes that the manufacturing of Berubicin will begin at Pii during the third quarter of 2020. With this success, CNS hopes to start its Phase 2 trials in the United States during the first quarter of 2021 as well.

“As we prepare to initiate our upcoming Berubicin clinical trials, our execution both on the clinical and manufacturing fronts remain paramount to our success,” CNS Pharmaceuticals CEO John Climaco said. “We continue to be encouraged as our partner Pii has now delivered upon many of the critical steps necessary to ensure the quality and availability of Berubicin. We look forward to keeping you updated on our progress as we continue our preparations to submit an IND for Berubicin during the fourth quarter of this year.”

For more information, visit the company’s website at www.CNSPharma.com.

• Worldwide number of esports gamers predicted to reach 2.7 billion this year
• Pandemic forced closure of traditional sports, leaving sports bettors with few options
• Mobius CEO Lynn Pearce notes it is “remarkably interesting to see how much money is being raised for those participating in the esports arena”

In the wake of COVID-19, eSports is gaining exposure and popularity with a predicted 2.7 billion gamers playing worldwide by the end of this year, says Mobius Interactive CEO Lynn Pearce in the most recent issue of “Infinity Gaming” (http://ibn.fm/Rpsux). Pearce, an experienced, data-driven, commercially focused, strategic brand marketer with more than 15 years of proven success in the global gaming industry, authored “The Rise of eSports,” a feature article in the magazine focused on how the worldwide pandemic has sparked growing popularity for the once little-known gaming industry.

“For the past few years,” Pearce writes, “as an igaming consultant, I really got into the esports frame of mind and tried to convince the online sports betting companies to include esports in their product offerings, and even though they were not against the idea in general, some of them were actually quite willing to add in this product vertical, they never really put their money where their mouth was.”

The challenges, Pearce notes, was that it was difficult to monetize esports and there was a general lack of knowledge about esports and how to market it. In addition, she observes, “esports games take place over a longer period than regular sports — and sports bettors . . . generally want more instant action, resulting in a lack of interest overall.”

Until the sports world ground to a halt as a result of COVID-19. The pandemic forced the closure of traditional sports, Pearce says, which left sports bettors with few options. “They turned to esports and the rest, as they say, is history. Even after sports started to re-open, the rise of esports has continued and is gaining momentum,” she writes.

In fact, Pearce reports, “by the end of this year, there will be 2.7 billion gamers worldwide, with 2.5 billion playing on mobile, 1.3 billion playing on PC, and 0.8 billion on console. The year 2023 will mark a major milestone for the global games market. That year, the global number of players will surpass the three-billion mark!”

As a result of the growing popularity of esports, Pearce also notes that “it is remarkably interesting to see how much money is being raised for those participating in the esports arena, regardless of industry. In this past week alone, I have read of many companies that have successfully announced millions in funding.”

Pearce, who herself is at the helm of Mobius Interactive, a new online gaming operator, notes that the company is being approached by esports companies and esports communities to be involved in the re-opening of local offline events as they take place, “and we are very excited to be involved in this growing and thriving community. . . . I am betting on the growth of esports.”

Mobius Interactive is an online gaming operator featuring a variety of unique offerings catering to diverse demographic groups. Mobius Interactive’s team has extensive senior-management experience across business-to-consumer (“B2C”) and business-to-business (“B2B”) marketing in the iGaming industry, specializing in eSports, sports betting, casino and live casino. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates.

For more information, visit the company’s website at www.MobiusInteractive.Ltd.

NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion
• Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments
• As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces.

In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://ibn.fm/1UQMB).

At the same time, the psychedelic drugs market is also projected to reach $6.85 billion by 2027. That forecast is based on increased incidences of mental health disorders as well as growing acceptance of psychedelic drugs. The expected proliferation of psychedelics comes from continued research interest from major academic institutions (http://ibn.fm/g75oV).

Cybin is committed to advancing research and development (R&D) through its intellectual property portfolio in the psychedelic, pharmaceutical and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.

The company’s business model is structured around two wholly owned divisions across the pharmaceutical and nutraceutical sector: Serenity Life Sciences and Nature’s Journey Inc. Serenity Life Sciences is focused on advancing R&D of psilocybin-based pharmaceutical products. Psilocybin, a naturally occurring, non-habit-forming psychedelic compound derived from mushrooms, is experiencing a strong research revival.

Studies show promising results in the treatment of a number of mental health conditions such as anxiety, depression, PTSD, addiction, eating disorders, ADHD and other conditions (http://ibn.fm/2vOww). Cybin views mushroom-derived psychedelic medicines as brain boosters potentially capable of breaking negative thought patterns. Studies indicate that retraining thought processes with low doses of psychedelics help with mental health conditions affecting hundreds of millions of people worldwide.

Cybin’s Nature’s Journey Inc. is focused on nonpsychedelic medical mushroom extracts. Consumer trend forecasts indicate that adaptogenic mushrooms are the next wave of super nutraceuticals. These products are designed to optimize overall health by enhancing mental wellness, immune-boosting detoxification and general well-being.

Cybin offers a robust, diversified business model with compelling growth opportunities in dual, complimentary sectors. Therefore, investors looking for high-potential investments in growing markets should take note of the company’s two-pronged approach to the psychedelic pharmaceutical and nutraceutical mushroom markets.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• The annual Precious Metals Summit at Beaver Creek is marking its 10th anniversary with its usual select slate of mining industry interests in an online format designed to be health-conscious amid the ongoing COVID-19 pandemic
• The conference began its three-day lineup of more than 250 company presenters, which began Tuesday, Sept. 15, concluding Sept. 17
• The Beaver Creek Precious Metals Summit is a by-invitation event that brings together significant investors and corporate executives with some of the world’s most prospective junior miners
• Concerns about the pandemic’s impact on economies worldwide have been accompanied by increased interest in gold and other precious metals, making the conference timelier than ever

The 10th annual Beaver Creek Precious Metals Summit launched Tuesday, Sept. 15 with a three-day lineup of over 250 mining companies presenting on their operations within a pandemic-excited market for gold, silver, and other key ores (http://ibn.fm/V2dPn).

The 2020 Precious Metals Summit Beaver Creek (Virtual) is one of the year’s key conferences in the sector, bringing together a by-invitation community of institutional investors, sell-side representatives and corporate executives from senior precious metals companies to meet and network with some of the world’s most prospective junior producers, explorers and developers.

Although the COVID-19 pandemic and ongoing corporate travel restrictions have impacted the business summit network, Beaver Creek is experienced in developing virtual contacts through webcasts. Last year’s summit at the Beaver Creek Resort in the Rockies west of Denver drew 14,332 webcast viewers during the week of the summit and another 14,434 individuals the following week (http://ibn.fm/H9vU0).

The 2019 summit included more than 400 buy-side delegates, and the average number of meetings per mining company jumped from 25 to 34, according to event organizers.

Kitco News reported recently that financing tracker Oreninc has noted some “exceptional” weeks for juniors this year as they’ve raised funds on the back of higher precious metal prices and easy access to capital. Those trends have accompanied economic battering by the worldwide contagion as it has led to huge job losses and restrictions on businesses’ in-person operations.

“[Juniors] have raised a lot of cash in the last few months. Everybody’s excited about the higher gold price,” Resources Opportunities podcast editor James Kwantes told Kitco (http://ibn.fm/ud2dm). “It will be interesting to see what happens when all the holds come off in the four-month paper. … Financings typically have a four-month hold placed on them. So if you buy into a private placement, you can’t do anything with the stock for four months. Typically, the company will try to generate news or hopefully make a deposit — make a discovery.”

The dozens of companies participating in this year’s Beaver Creek virtual summit will be available to participate in one-on-one meetings with qualified investors and corporate development teams.

The summit helps monied interests identify emerging growth companies with the potential for high returns in the future. The keynote and company presentations conclude Thursday, Sept. 17 with a panel discussing lessons learned from resource investing in a pandemic.

For more information visit the event’s website at www.PreciousSummit.com.

• “Mushrooms are having a moment,” reports “Forbes” article
• Sector projected to benefit from both users, investors
• Pure Extracts Technologies well positioned to partner with organizations eyeing development in both functional, psychedelic products

In what “Forbes” magazine is calling a “moment,” mushrooms are seeing rising popularity as growing numbers of people are interested in using the fungi as well as investing in them. This is great news for companies such as Pure Extract Technologies (“Pure Extracts”), a Canadian plant-based extraction company entering the functional medicinal mushroom space and collaborating in the psychedelic space

“Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades,” observes the article, titled “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health” (http://ibn.fm/10yfG). “In 2020, whether consuming, investing, or both, mushrooms are having a moment.” The article, which notes psychedelics’ potential to impact and improve mental health, mentions several upcoming events focused on psychedelic science, innovation and investment opportunities.

These events lend validity to the expanding psychedelic — and functional — mushroom market. Projections call for the global functional mushroom market to grow by a CAGR of 8.04% from 2019 through 2024 (http://ibn.fm/EVDxw), as functional mushrooms are used in a variety of health-care and pharmaceutical products. In addition, the depression medication market, where psychedelic mushrooms are showing strong potential, was projected to grow from $14.5 billion in 2014 to nearly $17.0 billion this year (http://ibn.fm/yoIoo).

Pure Extracts is well positioned to partner with organizations eyeing development in both functional and psychedelic products. The Company’s business model consists of three verticals: in-house brands; toll processing, or offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, or supplying products in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

In addition, Pure Extracts is applying for a Natural Health Products site license from Health Canada, which will enable the production and sales of functional mushroom products in an EU-GMP-compliant environment. Once EU-GMP certified, the products the Company produces in its 10,000-square-foot will qualify for international sales including in Germany where the importation regulations are among the strictest in the world. Finally, Pure Extracts is exploring several joint-development possibilities for Q4 2020 product launches.

Pure Extract Technologies Inc., headquartered in Pemberton British Columbia, is a soon-to-be public, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be a dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://ibn.fm/Pure

• Predictive Oncology presenting at upcoming LD 500 investor conference
• Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe
• Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://ibn.fm/42UBB). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.

LD Micro, the organizer of the LD 500 conference, was founded in 2006 with the purpose of providing an independent news resource for investors focusing on the microcap space. Initially a newsletter highlighting unique companies, the event has transformed itself into a series of influential conferences held annually– bringing together some of today’s most interesting smaller and micro-cap publicly listed companies and investors focusing on the space.

The LD 500 conference will be the company’s most ambitious event to date, hosting a selection of 500 of North America’s most promising micro-cap companies over a series of four days. The virtual event is set to include a series of keynote addresses and one-on-one meetings, where investors will be able to meet with corporate management teams to receive updates on ongoing corporate operations while posing queries of their own.

“We are delighted to be hosting our virtual event in order to showcase some of the truly unique names in micro-cap,” stated LD Micro president Chris Lahiji. “There are many people and companies who are unable to attend our live events, due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure.”

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. Through its subsidiary Helomics, POAI is bringing this cutting-edge technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors response to drugs. These models can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://ibn.fm/YWbtr).

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• 180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses
• The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later this year
• Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent
• 180 Life Sciences is completing phase 2b/3 clinical trials tackling fibrosis and inflammation-causing TNF substance aberrations

The sudden and surprise impact of the COVID-19 pandemic this year has drawn new attention to the bioreactive intricacies of the inflammatory process (http://ibn.fm/tWUgV) as medical scientists work feverishly to develop a clear response to the crisis that has killed some 900,000 people worldwide (as of September 2020) with millions more seriously affected (http://ibn.fm/U1hfy). Even before the virus began its sweep, inflammation was receiving critical attention from rheumatologists because of its significance to a wide array of diseases including arthritis, asthma, psoriasis, and many bowel diseases (http://ibn.fm/aF04C).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are scheduled to begin later this year, and two additional programs are in the preclinical stage.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), recently obtained bridge financing to acquire 180 Life Sciences, a process it expects to complete in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ATNF, according to a June news release (http://ibn.fm/YVZ2o).

KBLM has filed its amended S4 with the SEC on August 28, 2020 which is pending SEC clearance.

KBLM has valued 180 Life Sciences at $175 million at a time when analysts with Fortune Business Insights anticipate the anti-inflammatory therapeutics market will grow with a 9.3 percent CAGR through 2027 to generate revenues of $191.42 billion (http://ibn.fm/IEHIX).

The company’s phase 2b/3 clinical trials are tackling fibrosis and anti-TNF therapies related to early stage Dupuytren’s disease, frozen shoulder, and post-operative cognitive deficit, while preclinical studies are looking at liver fibrosis and nonalcoholic steatohepatitis.

Two other preclinical studies are tackling inflammatory pain and ulcerative colitis in ex-smokers. Developments in the anti-inflammatory therapeutics field aim to deliver medical responses that have less serious side effects than existing conventional treatments, through more effective targeting of specific conditions.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that are on the market and have improved the lives of millions of people and created companies that were later sold for billions of dollars. We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner,” KBL Merger Corp. CEO Dr. Marlene Krauss stated in the June news release.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

• The Movie Studio retains AdvisoryCloud to help identify, appoint company’s advisory board
• Growth of OTT media market in 2020 has led to significant growth in streaming audiences, leading to commensurate increase in demand for original content programming
• The Movie Studio has sought to capitalize on this trend by launching its own streaming platform, syndicating self-produced original content
• Coordination with AdvisoryCloud will assist MVES by providing it with highly experienced advisors adept at advancing companies’ growth trajectory

The Movie Studio (OTC: MVES), an independent Florida-based film studio, has announced that it has retained the services of AdvisoryCloud, a leading platform for advisors, to provide the company with advisory services as well as to assist in identifying and appointing expert advisors to The Movie Studio’s advisory board who could help add value to the company (http://ibn.fm/iCW5D).

AdvisoryCloud provides a platform enabling highly experienced executives to take a proactive approach in landing advisory work. With over 12,000 advisors on its platform, the company allows companies – ranging from start-ups to multi-national corporations – to assemble advisory boards of over 100 senior executives in a matter of weeks. In turn, companies are able to share their challenges and opportunities through a series of quarterly advisor briefings, receiving direct responses with unique advice, diverse suggestions and specific solutions from their highly specialized advisory team.

“One of the greatest resources available to any company proactively seeking advantages that can help their business succeed is the knowledge of advisors,” said AdvisoryCloud founder and CEO Jonathan Aspatore. “We are excited to connect The Movie Studio with a team of high-caliber advisors through our virtual advisory board services to provide the unique expertise and firsthand experiences needed to help take this company to the next level.”

The growth of the over-the-top media (“OTT”) sector, which encompasses audio, video and other media content delivered over the Internet, has witnessed a stunning surge in popularity over recent months – with the growth in OTT viewing rising by 196% year-over-year in April this year. The trend has proven to be highly favorable for The Movie Studio, and the company responded by launching its own eponymous platform featuring a wide variety of original content as well as movies drawn from a number of libraries acquired by the studio over the years.

The Movie Studio has capitalized on the ongoing growth in the online streaming industry over the past 24 months, which has seen the launch of a myriad of platforms—including the likes of Apple Plus, Disney Plus, HBO Max and NBC Universal’s Peacock—by licensing its original content through partnerships with Filmhub and BING Networks LLC.

This move has allowed the company to syndicate and monetize its motion pictures in a number of different global jurisdictions, further boosting their available revenue streams. Now, through its recently announced tie-up with AdvisoryCloud, The Movie Studio has sought to take the next step in developing its burgeoning film business.

“We look forward to utilizing AdvisoryCloud’s resources to provide critical evaluation of the company’s business mode, OTT platform and potential alignment of business verticals including potential M&A opportunities,” noted The Movie Studio CEO Gordon Scott Venters. “We are confident AdvisoryCloud could bring added value as a strategic partner regarding our business initiatives.”

For more information about the company, visit www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES